phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion (vol 10, pg 28, 2012)

被引：0

作者：

Hamilton, Erika ^{[1
]}

Blackwell, Kimberly ^{[1
]}

Hobeika, Amy C. ^{[2
]}

Clay, Timothy M. ^{[3
]}

Broadwater, Gloria ^{[4
]}

Ren, Xiu-Rong ^{[5
]}

Chen, Wei ^{[5
]}

Castro, Henry ^{[3
]}

Lehmann, Frederic ^{[3
]}

Spector, Neil ^{[1
]}

Wei, Junping ^{[6
]}

Osada, Takuya ^{[6
]}

Lyerly, H. Kim ^{[2
]}

Morse, Michael A. ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA

[2] Duke Univ, Med Ctr, Dept Surg, Div Gen Surg, Durham, NC 27710 USA

[3] GlaxoSmithKline Biol, Rixensart, Belgium

[4] Duke Canc Inst, Canc Stat Ctr, Durham, NC USA

[5] Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA

[6] Duke Univ, Med Ctr, Dept Surg, Div Surg Sci, Durham, NC 27710 USA

来源：

JOURNAL OF TRANSLATIONAL MEDICINE | 2013年 / 11卷

关键词：

D O I：

10.1186/1479-5876-11-82

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

[No abstract available]

引用

页数：1

共 50 条

[41] The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
Yajing Zhu
Ioannis Zerdes
Alexios Matikas
Ivette Raices Cruz
Mattias Bergqvist
Ellinor Elinder
Ana Bosch
Henrik Lindman
Zakaria Einbeigi
Anne Andersson
Lena Carlsson
Ann Charlotte Dreifaldt
Erika Isaksson-Friman
Mats Hellstrom
Hemming Johansson
Kang Wang
Jonas C. S. Bergh
Thomas Hatschek
Theodoros Foukakis
Breast Cancer Research and Treatment, 2024, 204 : 299 - 308
[42] A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies
Lynce, Filipa
Wang, Hongkun
Petricoin, Emanuel F.
Pohlmann, Paula R.
Smaglo, Brandon
Hwang, Jimmy
He, Aiwu R.
Subramaniam, Deepa S.
Deeken, John
Marshall, John
Pishvaian, Michael J.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (05) : 1145 - 1151
[43] The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
Zhu, Yajing
Zerdes, Ioannis
Matikas, Alexios
Cruz, Ivette Raices
Bergqvist, Mattias
Elinder, Ellinor
Bosch, Ana
Lindman, Henrik
Einbeigi, Zakaria
Andersson, Anne
Carlsson, Lena
Dreifaldt, Ann Charlotte
Isaksson-Friman, Erika
Hellstrom, Mats
Johansson, Hemming
Wang, Kang
Bergh, Jonas C. S.
Hatschek, Thomas
Foukakis, Theodoros
BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (02) : 299 - 308
[44] Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer
Lum, Lawrence G.
Al-Kadhimi, Zaid
Deol, Abhinav
Kondadasula, Vidya
Schalk, Dana
Tomashewski, Elyse
Steele, Patricia
Fields, Kristie
Giroux, Melissa
Liu, Qin
Flaherty, Lawrence
Simon, Michael
Thakur, Archana
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)
[45] Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
Maeng, Hoyoung M.
Moore, Brittni N.
Bagheri, Hadi
Steinberg, Seth M.
Inglefield, Jon
Dunham, Kim
Wei, Wei-Zen
Morris, John C.
Terabe, Masaki
England, Lee C.
Roberson, Brenda
Rosing, Douglas
Sachdev, Vandana
Pack, Svetlana D.
Miettinen, Markku M.
Barr, Frederic G.
Weiner, Louis M.
Panch, Sandhya
Stroncek, David F.
Wood, Lauren V.
Berzofsky, Jay A.
FRONTIERS IN ONCOLOGY, 2021, 11
[46] A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+metastatic breast cancer (MBC)
Ferrario, C.
Hamilton, E.
Aucoin, N.
Falkson, C. L.
Khan, Q.
Krop, I. E.
Welch, S.
Bedard, P. L.
Conlin, A.
Chaves, J.
Vo, A.
Walker, L.
Borges, V.
CANCER RESEARCH, 2016, 76
[47] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with adotrastuzumab emtansine (T-DM1), in HER2+metastatic breast cancer (MBC)
Borges, Virginia F.
Hamilton, Erika Paige
Yardley, Denise A.
Moulder, Stacy L.
Hortobagyi, Gabriel N.
Walker, Luke N.
Krop, Ian E.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[48] Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Metzger Filho, Otto
Viale, Giuseppe
Stein, Shayna
Trippa, Lorenzo
Yardley, Denise A.
Mayer, Ingrid A.
Abramson, Vandana G.
Arteaga, Carlos L.
Spring, Laura M.
Waks, Adrienne G.
Wrabel, Eileen
DeMeo, Michelle K.
Bardia, Aditya
Dell'Orto, Patrizia
Russo, Leila
King, Tari A.
Polyak, Kornelia
Michor, Franziska
Winer, Eric P.
Krop, Ian E.
CANCER DISCOVERY, 2021, 11 (10) : 2474 - 2487
[49] HER2 discordant results in local vs. central testing in the phase 3 nelipepimut-S trial and implementation of Leica Bond Oracle HER2 Immunohistochemistry (IHC) System for low and intermediate levels (1+,2+) of HER2 protein expression as a companion diagn
Melisko, Michelle
Mittendorf, Elizabeth A.
Safina, Sufia
Schenker, Michael
Brunt, Murray A.
Litwiniuk, Maria
Mackey, John
Petrakova, Katarina
Alieva, Svitiana
Chance, Lacey
Choy, Gavin S.
Ahn, Mark
Hamm, Adamm
Kumar, Sonia
Rugo, Hope S.
CANCER RESEARCH, 2015, 75
[50] Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY" phase 1-2 trial
Assenat, Eric
Azria, David
Mollevi, Caroline
Guimbaud, Rosine
Tubiana-Mathieu, Nicole
Smith, Denis
Delord, Jean-Pierre
Samalin, Emmanuelle
Portales, Fabienne
Larbouret, Christel
Robert, Bruno
Bibeau, Frederic
Bleuse, Jean-Pierre
Crapez, Evelyne
Ychou, Marc
Pelegrin, Andre
ONCOTARGET, 2015, 6 (14) : 12796 - 12808

← 1 2 3 4 5 →